A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.

Values of area under the ROC calculated from all 381 samples for all mutations displayed highly significant values when compared with all mutations (p=0.0001; binomial exact test) suggesting that any mutation signature is able, to partially discriminate other types of mutations (supplementary table S4).

also in 132,142 other papers